Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy

J Thromb Thrombolysis. 2009 Feb;27(2):135-40. doi: 10.1007/s11239-007-0169-7. Epub 2007 Dec 4.

Abstract

Background: This study investigated the effect of either oral or transdermal hormone replacement therapy (HRT) on haemostatic, fibrinolytic and lipid profiles in a group of Brazilian women 3 months after beginning treatment by comparing these results with those obtained immediately before HRT.

Methods: Plasma levels of TAT, DDi, F1+2, PC, PS, AT, PAI-1 and serum lipids were determined in blood samples collected from 24 women undergoing oral HRT and from 11 women undergoing transdermal HRT.

Results: Significant increases in DDi and F1+2 plasma levels were observed after 3 months of oral HRT, while PS levels decreased. After transdermal HRT, a significant decrease was observed only for AT levels.

Conclusion: After 3 months of oral HRT and in the absence of major genetic and acquired risk factors, women displayed a predisposition for activation of blood coagulation, and an increased activity of the fibrinolytic system. Oral HRT seemed to be more effective in predisposing haemostatic changes as compared to transdermal.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Aged
  • Biomarkers / blood
  • Blood Coagulation
  • Brazil / epidemiology
  • Female
  • Fibrinolysis
  • Hemostasis / drug effects
  • Hormone Replacement Therapy / adverse effects*
  • Humans
  • Lipids / blood*
  • Middle Aged
  • Postmenopause
  • Thrombophilia / blood
  • Thrombophilia / chemically induced*

Substances

  • Biomarkers
  • Lipids